Search research articles
Contact Us
Filters
Showing results (81-90 of 130) with videos related to
Page
of 13
Sort By:
JAAD International
|
March 28, 2024
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
Jonathan I Silverberg, Angel Cronin, Eric A Jones, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis
Hema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.
The British Journal of Dermatology
|
January 23, 2025
Global Delphi consensus on treatment goals for generalized pustular psoriasis
Jonathan N Barker, Emmylou Casanova, Siew Eng Choon, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
JAMA Dermatology
|
December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial
Kim A Papp, Kenneth Gordon, Bruce Strober, et al.
Dermatology Online Journal
|
October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panel
Angela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
Dermatology and Therapy
|
May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Richard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
International Journal of Dermatology
|
November 1, 2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis
Bruce Strober, Yang Zhao, Mary Helen Tran, et al.
Journal of the American Academy of Dermatology
|
February 5, 2026
Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial
Richard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
Dermatology and Therapy
|
February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 130) with videos related to
Sort By:
Page
of 13
JAAD International
|
March 28, 2024
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
Jonathan I Silverberg, Angel Cronin, Eric A Jones, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis
Hema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.
The British Journal of Dermatology
|
January 23, 2025
Global Delphi consensus on treatment goals for generalized pustular psoriasis
Jonathan N Barker, Emmylou Casanova, Siew Eng Choon, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
JAMA Dermatology
|
December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial
Kim A Papp, Kenneth Gordon, Bruce Strober, et al.
Dermatology Online Journal
|
October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panel
Angela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
Dermatology and Therapy
|
May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Richard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
International Journal of Dermatology
|
November 1, 2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis
Bruce Strober, Yang Zhao, Mary Helen Tran, et al.
Journal of the American Academy of Dermatology
|
February 5, 2026
Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial
Richard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
Dermatology and Therapy
|
February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Page
of 13